Горбунов В. М. ВАРИАБЕЛЬНОСТЬ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ КАК НОВАЯ МИШЕНЬ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ: ФОКУС НА ФИКСИРОВАННУЮ КОМБИНАЦИЮ АМЛОДИПИНА И ПЕРИНДОПРИЛА АРГИНИН. Российский кардиологический журнал. 2012;(5):98-104.
1. Clement D.L., De Buyzere M.L., De Bacquer D.A. et al. Prognostic value of ambulatory bloodpressure recordings in patients with treated hypertension. New Engl J Med 2003; 348:2407– 2415.
2. Dolan E., Stanton A.V., Thom S. et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2008; 27:876–885.
3. Mancia G.,Ferrari A.,Gregorini L.etal.Bloodpressureandheartratevariabilities innormotensive and hypertensive human beings. Circ Res 1983; 53:96–104.
4. Rogoza A.N., Nikolsky V.P., Oschepkova E.V. et al. 24-hour blood pressure monitoring (methodologicalaspects,Moscow,1996,36p.(РогозаА.Н.,Никольский В.П.,Ощепкова Е.В. и соавт. Суточное мониторирование артериального давления при гипертонии (методиче- ские вопросы). М., 1996, 36 с.)
5. Parati G., Faini G., Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Res 2006; 8:199–204.
6. Kikuya M., Ohkubo T., Metoki H. et al. Day-to-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 2008:52:1045–1050.
7. Rothwell P.M., Howard S.C., Dolan E. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet 2010; 375:895–905.
8. Mena L., Pintos S., Queipo N.V. A reliable index for the prognostic significance of blood pressure variability. J Hypertens 2003; 23: 505–511.
9. Stolarz-Skrzypek K,, Thijs L., Richart T. et al. Blood pressure variability in relation to outcome in the international Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hyp Res 2010; 33:757–766.
10. Rothwell P. Does blood pressure variability modulates cardiovascular risk? Curr Hypertens Rep 2011; 13:177–186.
11. Farrell B., Godwin J., Richards S., Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044–1054.
12. The ESPS Group. The European Stroke Prevention Study (ESPS). Principal end-points. Lancet, 1987; 330:1351–54.
13. The Dutch TIA Study Group, A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patient after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325:1261–66.
14. Poulter N.R., Wedel H., Dahl√f B. et al. Foe the ASCOT investigators.Role of blood pressure and other variables in the differential cardiovascular events rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial –BloodPressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907– 13.
15. Muntner P., Schimbo D., Tonelli M. et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011; 57:160–6.
16. Geeganage C., Tracy M., England T. et al. TAIST Investigators. Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke 2011; 42:491–493.
17. Zhang Y., Agnoletti D., Safar M.E. et al. Effect of Antihypertensive agents on blood pressure variability. The Natrilix SR versus Candesartan and Amlodipine in the Reduction of Systolic Blood Pressure in Hypertensive Patients (X–CELLENT) Study. Hypertension 2011; 58:155–60.
18. Debire H., Lacolley P., Chaoche-Teyara K. et al. Relationship between arterial distensibility and low-frequency power spectrum of blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002;39:98–106.
19. Law M. R., Morris J. K., Wald N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.doi:10.1136/bmj.b1665.
20. Rothwell P. M., Howard S. C., Dolan E. et al. Effects of ß-blockers and calcium channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9:469–80.
21. Rothwell P. M. Limitations of usual pressure hypothesis and the importance of variability, instability and episodic hypertension. Lancet 2010; 375:938–48.
22. Leonova M. V. Clinical pharmacology of the combination of ACE inhibitors and calcium antagonists: benefits of the perindopril arginine and amlodipine combination. Cardiovascular therapy and prevention, V.9., N 8, 2010, pp. 55–62. (Леонова М. В. Клиническая фармакология комбинации ингибиторов ангиотензин-превращающего фермента и антагонистов кальция: преимущества комбинации периндоприла аргинина и амлодипина. Кардиоваскулярная терапия и профи- лактика 2010; 8:55–62).
23. Asmar R., Topouchian J., Pannier B. et al; “Pulse wave velocity as endpoint in largescale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study”, J Hypertens 2001; 19 (4):813– 818.
24. Ferreri R. Optimizing the treatment of hypertebsion and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 2008; 24 (12):3543–57.
25. Fogari R., Zoppi A., Mugellini A. et al. Effects of amlodipine, nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebo controlled, double-masked, crossover study. Cur Therap Res 1999; 60 (3):121–8.
26. Sirenko Yu. N., Radchenko A. D., Dzyak G. V. et al. Results of Open Trial on Evaluation of Antihypertensive Efiicacy and Tolerance of Bi-prestarium Tretment in Patients with hewly Diagnosed or Uncontrolled Arterial Hypertension (Primary Results of PERSPECTIVE Trial). Arterial Hypertension; 4 (12):7–19. (Сиренко Ю. Н., Радченко А. А., Дзяк Г. В. и соавт. Результаты открытого исследования по оценке антигипертензивной эффективности и Переносимости Би-Престариума у пациентов с артериальной гипертензией, вновь диагностированной или не контролированной предыдущей терапией (Первичные результаты исследования ПЕРСПЕКТИВА). Артериальная Гипертензия 2010; 4 (12):7–19).
27. Williams B., Lacy P. S., Thom S. M. et al. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113:1213–25.
28. Duprez D. A., Jacobs Jr D. R., Lutsey P. L. et al. Race/ethnic and sex differences in large and small artery elasticity-results of the multi-ethnic study of atherosclerosis (MESA). Ethn Dis. 2009; 19:243–50. 29. Poulter N.R., Sever P.S. Anglo-Scandinavian Cardiac Outcomes Trial. Third edition, 2011, p. 42.
